Text stringlengths 636 34.6k |
|---|
Drug A is Abatacept. Drug B is Aldesleukin. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is Alectinib. The severity of the interaction is major. The metabolism of Alectinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can... |
Drug A is Abatacept. Drug B is Alemtuzumab. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is Alfentanil. The severity of the interaction is moderate. The metabolism of Alfentanil can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Allogeneic processed thymus tissue. The severity of the interaction is minor. The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Abatacept. Allogeneic processed thymus tissue for immune reconstitution therapy aims to restore the i... |
Drug A is Abatacept. Drug B is Almotriptan. The severity of the interaction is moderate. The metabolism of Almotriptan can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Alogliptin. The severity of the interaction is moderate. The metabolism of Alogliptin can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Alosetron. The severity of the interaction is moderate. The metabolism of Alosetron can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ... |
Drug A is Abatacept. Drug B is Alpelisib. The severity of the interaction is major. The metabolism of Alpelisib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can... |
Drug A is Abatacept. Drug B is Alprazolam. The severity of the interaction is moderate. The metabolism of Alprazolam can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Ambrisentan. The severity of the interaction is moderate. The metabolism of Ambrisentan can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Aminophylline. The severity of the interaction is major. The metabolism of Aminophylline can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine le... |
Drug A is Abatacept. Drug B is Amiodarone. The severity of the interaction is major. The metabolism of Amiodarone can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels c... |
Drug A is Abatacept. Drug B is Amitriptyline. The severity of the interaction is major. The metabolism of Amitriptyline can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine le... |
Drug A is Abatacept. Drug B is Amodiaquine. The severity of the interaction is moderate. The metabolism of Amodiaquine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Amoxapine. The severity of the interaction is major. The metabolism of Amoxapine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can... |
Drug A is Abatacept. Drug B is Amphetamine. The severity of the interaction is moderate. The metabolism of Amphetamine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Amsacrine. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Amsacrine is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to b... |
Drug A is Abatacept. Drug B is Anagrelide. The severity of the interaction is major. The metabolism of Anagrelide can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels c... |
Drug A is Abatacept. Drug B is Anakinra. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Anakinra is combined with Abatacept. Anakinra may enhance the adverse effects of Abatacept and increase the risk of infection. A 2006 randomized controlled trial found that ab... |
Drug A is Abatacept. Drug B is Anastrozole. The severity of the interaction is moderate. The metabolism of Anastrozole can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Anifrolumab. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Anifrolumab. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is Anthrax immune globulin human. The severity of the interaction is moderate. The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Abatacept. Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines a... |
Drug A is Abatacept. Drug B is Anthrax vaccine. The severity of the interaction is minor. The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Abatacept. Immunosuppressive therapies, including chemotherapy, corticosteroids (used in high-doses longer than 2 weeks), and radiation the... |
Drug A is Abatacept. Drug B is Antilymphocyte immunoglobulin (horse). The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Antilymphocyte immunoglobulin (horse). Immunosuppressive agents may exert an additive effect on other immunosuppressive... |
Drug A is Abatacept. Drug B is Antipyrine. The severity of the interaction is moderate. The metabolism of Antipyrine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Antithymocyte immunoglobulin (rabbit). The severity of the interaction is major. The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive... |
Drug A is Abatacept. Drug B is Apalutamide. The severity of the interaction is moderate. The metabolism of Apalutamide can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Apixaban. The severity of the interaction is moderate. The metabolism of Apixaban can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ca... |
Drug A is Abatacept. Drug B is Apomorphine. The severity of the interaction is moderate. The metabolism of Apomorphine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Apremilast. The severity of the interaction is major. The therapeutic efficacy of Apremilast can be decreased when used in combination with Abatacept. The concomitant administration of apremilast with biologics for rheumatoid arthritis treatment has not been formally evaluated. Several st... |
Drug A is Abatacept. Drug B is Aprepitant. The severity of the interaction is moderate. The metabolism of Aprepitant can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Arformoterol. The severity of the interaction is moderate. The metabolism of Arformoterol can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine l... |
Drug A is Abatacept. Drug B is Aripiprazole lauroxil. The severity of the interaction is moderate. The metabolism of Aripiprazole lauroxil can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that... |
Drug A is Abatacept. Drug B is Aripiprazole. The severity of the interaction is moderate. The metabolism of Aripiprazole can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine l... |
Drug A is Abatacept. Drug B is Arsenic trioxide. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infe... |
Drug A is Abatacept. Drug B is Asenapine. The severity of the interaction is moderate. The metabolism of Asenapine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ... |
Drug A is Abatacept. Drug B is Astemizole. The severity of the interaction is major. The metabolism of Astemizole can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels c... |
Drug A is Abatacept. Drug B is AstraZeneca COVID-19 Vaccine. The severity of the interaction is moderate. The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Abatacept. Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are... |
Drug A is Abatacept. Drug B is Asunaprevir. The severity of the interaction is moderate. The metabolism of Asunaprevir can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Atazanavir. The severity of the interaction is moderate. The metabolism of Atazanavir can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Atenolol. The severity of the interaction is moderate. The metabolism of Atenolol can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ca... |
Drug A is Abatacept. Drug B is Atomoxetine. The severity of the interaction is moderate. The metabolism of Atomoxetine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Atorvastatin. The severity of the interaction is moderate. The metabolism of Atorvastatin can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine l... |
Drug A is Abatacept. Drug B is Avacopan. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Avacopan. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bon... |
Drug A is Abatacept. Drug B is Avanafil. The severity of the interaction is moderate. The metabolism of Avanafil can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ca... |
Drug A is Abatacept. Drug B is Avapritinib. The severity of the interaction is moderate. The metabolism of Avapritinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Avatrombopag. The severity of the interaction is moderate. The metabolism of Avatrombopag can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine l... |
Drug A is Abatacept. Drug B is Axitinib. The severity of the interaction is major. The metabolism of Axitinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can n... |
Drug A is Abatacept. Drug B is Azacitidine. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Azacitidine is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is Azathioprine. The severity of the interaction is moderate. The metabolism of Azathioprine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine l... |
Drug A is Abatacept. Drug B is Azelastine. The severity of the interaction is moderate. The metabolism of Azelastine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Azithromycin. The severity of the interaction is moderate. The metabolism of Azithromycin can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine l... |
Drug A is Abatacept. Drug B is Bacillus calmette-guerin substrain russian BCG-I live antigen. The severity of the interaction is major. The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Abatacept. VERITY-BCG is a live BCG vaccine use... |
Drug A is Abatacept. Drug B is Bacillus calmette-guerin substrain tice live antigen. The severity of the interaction is major. The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept. In most cases, the coadministration of live vaccines and... |
Drug A is Abatacept. Drug B is Baricitinib. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Baricitinib. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is Basiliximab. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Basiliximab is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is BCG vaccine. The severity of the interaction is major. The risk or severity of infection can be increased when BCG vaccine is combined with Abatacept. In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled repli... |
Drug A is Abatacept. Drug B is Beclomethasone dipropionate. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to ... |
Drug A is Abatacept. Drug B is Belatacept. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Belatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to... |
Drug A is Abatacept. Drug B is Belimumab. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Belimumab. Belimumab is a biologic treatment used for individuals with lupus 2, abatacept is also a biological treatment 1. While being studied, it... |
Drug A is Abatacept. Drug B is Belinostat. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Belinostat. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to... |
Drug A is Abatacept. Drug B is Belumosudil. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Belumosudil. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is Belzutifan. The severity of the interaction is moderate. The metabolism of Belzutifan can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Bendamustine. The severity of the interaction is major. The metabolism of Bendamustine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine leve... |
Drug A is Abatacept. Drug B is Benzatropine. The severity of the interaction is moderate. The metabolism of Benzatropine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine l... |
Drug A is Abatacept. Drug B is Benzocaine. The severity of the interaction is moderate. The metabolism of Benzocaine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Benzphetamine. The severity of the interaction is moderate. The metabolism of Benzphetamine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine... |
Drug A is Abatacept. Drug B is Benzyl alcohol. The severity of the interaction is moderate. The metabolism of Benzyl alcohol can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytoki... |
Drug A is Abatacept. Drug B is Betamethasone. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Betamethasone is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection ... |
Drug A is Abatacept. Drug B is Betaxolol. The severity of the interaction is moderate. The metabolism of Betaxolol can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ... |
Drug A is Abatacept. Drug B is Bexarotene. The severity of the interaction is moderate. The metabolism of Bexarotene can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Bicalutamide. The severity of the interaction is major. The metabolism of Bicalutamide can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine leve... |
Drug A is Abatacept. Drug B is Bimekizumab. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Bimekizumab. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is Binimetinib. The severity of the interaction is major. The metabolism of Binimetinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels... |
Drug A is Abatacept. Drug B is Bleomycin. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Bleomycin is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to b... |
Drug A is Abatacept. Drug B is Blinatumomab. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Blinatumomab. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection du... |
Drug A is Abatacept. Drug B is Bortezomib. The severity of the interaction is major. The metabolism of Bortezomib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels c... |
Drug A is Abatacept. Drug B is Bosentan. The severity of the interaction is moderate. The metabolism of Bosentan can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ca... |
Drug A is Abatacept. Drug B is Bosutinib. The severity of the interaction is major. The metabolism of Bosutinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can... |
Drug A is Abatacept. Drug B is Brentuximab vedotin. The severity of the interaction is major. The metabolism of Brentuximab vedotin can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce... |
Drug A is Abatacept. Drug B is Brexpiprazole. The severity of the interaction is moderate. The metabolism of Brexpiprazole can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine... |
Drug A is Abatacept. Drug B is Brigatinib. The severity of the interaction is major. The metabolism of Brigatinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels c... |
Drug A is Abatacept. Drug B is Brivaracetam. The severity of the interaction is moderate. The metabolism of Brivaracetam can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine l... |
Drug A is Abatacept. Drug B is Brodalumab. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Brodalumab. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to... |
Drug A is Abatacept. Drug B is Bromazepam. The severity of the interaction is moderate. The metabolism of Bromazepam can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Bromotheophylline. The severity of the interaction is moderate. The metabolism of Bromotheophylline can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce ... |
Drug A is Abatacept. Drug B is Brompheniramine. The severity of the interaction is moderate. The metabolism of Brompheniramine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cyto... |
Drug A is Abatacept. Drug B is Budesonide. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Budesonide is combined with Abatacept. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to... |
Drug A is Abatacept. Drug B is Bupivacaine. The severity of the interaction is moderate. The metabolism of Bupivacaine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Buprenorphine. The severity of the interaction is moderate. The metabolism of Buprenorphine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine... |
Drug A is Abatacept. Drug B is Bupropion. The severity of the interaction is moderate. The metabolism of Bupropion can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ... |
Drug A is Abatacept. Drug B is Buspirone. The severity of the interaction is moderate. The metabolism of Buspirone can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ... |
Drug A is Abatacept. Drug B is Busulfan. The severity of the interaction is major. The metabolism of Busulfan can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can n... |
Drug A is Abatacept. Drug B is Cabazitaxel. The severity of the interaction is major. The metabolism of Cabazitaxel can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels... |
Drug A is Abatacept. Drug B is Cabergoline. The severity of the interaction is major. The metabolism of Cabergoline can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels... |
Drug A is Abatacept. Drug B is Cabozantinib. The severity of the interaction is major. The metabolism of Cabozantinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine leve... |
Drug A is Abatacept. Drug B is Caffeine. The severity of the interaction is moderate. The metabolism of Caffeine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ca... |
Drug A is Abatacept. Drug B is Canakinumab. The severity of the interaction is major. The risk or severity of adverse effects can be increased when Abatacept is combined with Canakinumab. Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due ... |
Drug A is Abatacept. Drug B is Candesartan cilexetil. The severity of the interaction is moderate. The metabolism of Candesartan cilexetil can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.